Virus infection-inhibiting molding, and production method of the same

Abstract

To provide a synthetic resin-made virus infection-inhibiting molding having excellent effect of inhibiting virus infection.SOLUTION: A virus infection-inhibiting molding includes: a synthetic resin; and a particulate virus infection-inhibiting agent contained in a dispersion state in the synthetic resin, where an aggregation degree of the particulate virus infection-inhibiting agent is controlled as a standard deviation σ of a volume fraction of the virus infection-inhibiting agent in a width direction measured by X-ray CT is 0.1 to 5, and a surface of the virus infection-inhibiting molding is configured so that the virus infection-inhibiting agent easily exists thereon while making a surface area of the particulate virus infection-inhibiting agent large to have excellent virus infection-inhibiting effect.SELECTED DRAWING: None

Description

[Technical field]

[0001] The present invention relates to a virus infection-preventing molded article and a method for producing the same. [Background technology]

[0002] In recent years, in addition to seasonal influenza virus epidemics, the novel coronavirus (COVID-19) has become a global pandemic.

[0003] Furthermore, there have been confirmed cases of highly pathogenic avian influenza viruses mutating and transmitting the virus to humans, and there are also concerns about the SARS virus, which has an extremely high mortality rate, which is causing growing anxiety about viruses.

[0004] To address these problems, Patent Document 1 proposes an antiviral synthetic resin composition that contains 0.5 parts by mass or more of a sulfonic acid surfactant per 100 parts by mass of synthetic resin. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] JP 2016-128395 A Summary of the Invention [Problem to be solved by the invention]

[0006] However, the above-mentioned antiviral synthetic resin composition is merely a synthetic resin containing a sulfonic acid surfactant, and the synthetic resin containing a sulfonic acid surfactant does not have sufficient antiviral properties (viral infection prevention effect), and a synthetic resin molded article having an excellent viral infection prevention effect is desired.

[0007] The present invention provides a virus infection-preventing molded article made of a synthetic resin, which has an excellent virus infection-preventing effect. [Means for solving the problem]

[0008] The virus infection-inhibiting molding of the present invention comprises a synthetic resin and a particulate virus infection inhibitor contained in a dispersed state in the synthetic resin, and is characterized in that the standard deviation σ of the volume fraction of the virus infection inhibitor in the width direction as measured by X-ray CT is 0.1 to 5.

[0009] The method for producing a virus infection-inhibiting molded article of the present invention is characterized by comprising a step of melt-kneading the particulate virus infection-inhibiting agent described above with a synthetic resin. Effect of the Invention

[0010] The virus infection-blocking molded article of the present invention has a standard deviation σ of the volume fraction of the virus infection inhibitor in the width direction measured by X-ray CT of 0.1 to 5, so that the degree of aggregation of the particulate virus infection inhibitor is controlled to increase the surface area of ​​the particulate virus infection inhibitor, while facilitating the presence of the virus infection inhibitor on the surface of the virus infection-blocking molded article. Therefore, the virus infection-blocking molded article has an excellent virus infection-blocking effect due to the virus infection inhibitor. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0011] The virus infection-inhibiting molding contains a synthetic resin and a particulate virus infection-inhibiting agent contained in a dispersed state in the synthetic resin, and the standard deviation σ of the volume fraction of the virus infection-inhibiting agent in the width direction measured by X-ray CT is 0.1 to 5.

[0012] The virus infection-blocking molded product has a particulate virus infection-blocking agent dispersed in a synthetic resin. The inventors have found through their research that the virus infection-blocking effect of the virus infection-blocking molded product cannot be effectively achieved by simply incorporating the virus infection-blocking agent in the synthetic resin.

[0013] The inventors focused on the dispersion state of a particulate virus infection inhibitor in a synthetic resin and discovered that by controlling the dispersion state of the virus infection inhibitor, the virus infection inhibitor's virus infection inhibitory effect can be effectively expressed, and as a result, an excellent virus infection inhibitory effect can be imparted to a virus infection inhibitor molding.

[0014] [Synthetic resin] The virus infection-preventing molded article contains a synthetic resin. Any synthetic resin that can be used to produce a molded article may be used. The synthetic resin is not particularly limited, and examples thereof include thermoplastic resins (e.g., polyolefin resins such as polyethylene and polypropylene, polyvinyl chloride, polystyrene, polyvinyl acetate, polystyrene, ABS resin, AS resin, polymethyl methacrylate, polyurethane, Teflon (registered trademark), acrylonitrile butadiene styrene resin, acrylonitrile styrene resin, acrylic resin, polyvinyl alcohol, polyamide, polyacetal, polycarbonate, modified polyphenylene ether, polyester, polyethylene terephthalate, polybutylene terephthalate, cyclic polyolefin, polyphenylene sulfide, polytetrafluoroethylene, polysulfone, polyether sulfone, polyarylate, polyether ether ketone, thermoplastic polyimide, polyamide imide, etc.), and thermosetting resins (e.g., phenolic resins, epoxy resins, melamine resins, urea resins, unsaturated polyester resins, alkyd resins, silicone resins, polyurethane, thermosetting polyimides, etc.). The synthetic resins may be used alone or in combination of two or more kinds.

[0015] [Virus infection inhibitor] The virus infection-blocking molded body contains a virus infection inhibitor. The virus infection-blocking molded body exerts a virus infection-blocking effect by the action of the virus infection inhibitor. The virus infection inhibitor is not particularly limited as long as it exerts a virus infection-blocking effect and is particulate. The virus infection inhibitor preferably contains at least one compound selected from organic acids, alkylbenzene sulfonates, and amine compounds as an active ingredient, more preferably contains at least one compound selected from organic acids and alkylbenzene sulfonates, and more preferably contains an organic acid. The active ingredient of the virus infection inhibitor is preferably at least one compound selected from organic acids, alkylbenzene sulfonates, and amine compounds, more preferably at least one compound selected from organic acids and alkylbenzene sulfonates, and more preferably an organic acid. It is preferable to use any one compound selected from organic acids, alkylbenzene sulfonates, and amine compounds as the virus infection inhibitor, more preferably to use any one compound selected from organic acids and alkylbenzene sulfonates as the virus infection inhibitor, and more preferably to use an organic acid as the virus infection inhibitor.

[0016] In the present invention, an organic compound refers to a compound containing at least one carbon (preferably two or more) and a carbon-hydrogen bond (CH bond) in the molecule.

[0017] Here, the viral infection inhibitory effect refers to an effect of eliminating or reducing the infectivity of a virus to a cell, or preventing the virus from proliferating in the cell even if the virus infects the cell. Examples of methods for confirming the presence or absence of such viral infectivity include ISO18184 and JIS L1922 for textile products, and ISO21702 for plastics and non-porous surface products other than textile products. Other examples include the plaque method and hemagglutination titer (HAU) measurement method described in "Medical and Pharmaceutical Virology" (first published in April 1990).

[0018] The virus infection inhibitory effect of the virus infection inhibitor can be measured, for example, as follows: 5 parts by mass of the virus infection inhibitor and 95 parts by mass of a synthetic resin are melt-kneaded and mixed to produce a resin composition, which is then press-molded to produce a sheet-like synthetic resin molded body with an average thickness of 1 mm. The surface of the obtained synthetic resin molded body is wiped with a flat square nonwoven fabric measuring 10 cm on a side by moving the nonwoven fabric back and forth 10 times, and this synthetic resin molded body is used as a test specimen.

[0019] The obtained test specimens are subjected to antiviral tests in accordance with ISO 21702. After the reaction, the virus suspension is subjected to the plaque method to measure the virus infectivity (common logarithm) (PFU / cm 2 ) is calculated.

[0020] A blank standard was prepared in the same manner as above, except that no virus infection inhibitor was added, and the virus infectivity (common logarithm value) (PFU / cm) was calculated based on this blank standard in the same manner as above. 2 ) is calculated.

[0021] The antiviral activity value is calculated by subtracting the viral infectivity of the test specimen from the viral infectivity of the blank reference specimen.

[0022] For the viral infection inhibitor, the antiviral activity value 10 minutes after the start of the reaction in an antiviral test in accordance with ISO 21702 is preferably 2.0 or more, more preferably 2.5 or more, and even more preferably 2.8 or more. Regardless of the type of virus to be evaluated, it is preferable that the antiviral activity value is 2.0 or more for at least one type of virus.

[0023] The virus infection inhibitor preferably contains an organic acid as an active ingredient. The organic acid is preferably an organic compound, and may be a polymer. The organic acid has a carboxy group (-COOH), a sulfo group (-SO3H), a phosphonic acid group [-P(=O)(OH)2], or a phosphate group [-OPO(OH)2] in the molecule, and may have only one of these functional groups or may have multiple types of functional groups. The organic acid preferably has a carboxy group, since the virus infection inhibitor has an excellent virus infection inhibitory effect.

[0024] The content of the organic acid in the viral infection inhibitor is preferably 50% by mass or more, more preferably 60% by mass or more, more preferably 70% by mass or more, more preferably 80% by mass or more, more preferably 90% by mass or more, more preferably 95% by mass or more, more preferably 99% by mass or more, and more preferably 100% by mass.

[0025] The organic acid preferably has a plurality of functional groups selected from the group consisting of a carboxy group (-COOH), a sulfo group (-SO3H), a phosphonic acid group [-P(=O)(OH)2] and a phosphate group [-OPO(OH)2] in the molecule, more preferably a carboxy group is included in the plurality of functional groups, and more preferably a plurality of carboxy groups. When the organic acid has a plurality of the above functional groups, the virus infection-inhibiting molded article exhibits an excellent virus infection-inhibiting effect. It is preferable that the organic acid does not contain a salt of a sulfo group, a salt of a phosphonic acid group [-P(=O)(OH)2] and a salt of a phosphate group [-OPO(OH)2] in the molecule.

[0026] The organic acid is not particularly limited as long as it has a carboxy group (-COOH), a sulfo group (-SO3H), a phosphonic acid group [-P(=O)(OH)2] or a phosphoric acid group [-OPO(OH)2] in the molecule.

[0027] Examples of organic acids include adipic acid (solubility: 14 g / L), benzoic acid (solubility: 3.4 g / L), lauric acid (solubility: 0 g / L), azelaic acid (solubility: 2.4 g / L), sebacic acid (solubility: 0.25 g / L), dodecanedioic acid (solubility: 0 g / L), fumaric acid (solubility: 6.3 g / L), phthalic acid (solubility: 7.2 g / L), isophthalic acid (solubility: 0.13 g / L), and tetrahydrofuran (TFA) (solubility: 0.25 g / L). L), terephthalic acid (solubility: 0.017 g / L), methylenedisalicylic acid (solubility: 0 g / L), cis-Δ4-tetrahydrophthalic acid (solubility: 0 g / L), caproic acid (solubility: 11 g / L), enanthic acid (solubility: 2.4 g / L), caprylic acid (solubility: 0.68 g / L), pelargonic acid (solubility: 0.28 g / L), capric acid (solubility: 0.15 g / L), lauryl ester (solubility: 0.017 g / L), terephthalic acid (solubility: 0.017 g / L), methylenedisalicylic acid (solubility: 0 g / L), cis-Δ4-tetrahydrophthalic acid (solubility: 0 g / L), caproic acid (solubility: 0.017 g / L), Acid (solubility: 0.0048g / L), Myristic acid (solubility: 0g / L), Palmitic acid (solubility: 0g / L), Stearic acid (solubility: 0g / L), Myristoleic acid (solubility: 0g / L), Oleic acid (solubility: 0g / L), Ricinoleic acid (solubility: 0g / L), Salicylic acid (solubility: 2.0g / L), Gallic acid hydrate (solubility: 11g / L), Benzilic acid (solubility: 1 .4g / L), 4-aminobenzoic acid (solubility: 6g / L), triglycolaminic acid (solubility: 1.3g / L), polyacrylic acid (solubility: 250g / L or more), 1,3-propanediaminetetraacetic acid (solubility: 9g / L), diethylenetriaminepentaacetic acid (solubility: 4g / L), alginic acid (solubility: 0g / L), etc. are included, and isophthalic acid, terephthalic acid, and alginic acid are preferred. The solubility listed in parentheses is the solubility of the organic acid in water at 25°C. The organic acids may be used alone or in combination of two or more.

[0028] When the organic acid is a polymer, examples of the organic acid include a polymer having a carboxy group (-COOH), a sulfo group (-SOH), a phosphonic acid group [-P(=O)(OH)] or a phosphoric acid group [-OPO(OH)] in the side chain of a linear polymer.

[0029] In the case of a polymer having a carboxy group (-COOH), a sulfo group (-SOH), a phosphonic acid group [-P(=O)(OH)2] or a phosphoric acid group [-OPO(OH)2] in a side chain of the linear polymer, the linear polymer is not particularly limited, and for example, vinyl polymer, polyester, and polyurethane are preferable, and vinyl polymer is preferable.

[0030] The polymer having a carboxy group (-COOH), a sulfo group (-SOH), a phosphonic acid group [-P(=O)(OH)2] or a phosphate group [-OPO(OH)2] in the side chain of the linear polymer is not particularly limited, and examples thereof include a polymer containing a monomer component having a carboxy group, a polymer containing a monomer component having a sulfo group, a polymer containing a monomer component having a phosphonic acid group [-P(=O)(OH)2], a polymer containing a monomer component having a phosphate group [-OPO(OH)2], and the like.

[0031] Examples of monomers having a carboxy group include acrylic acid, methacrylic acid, acrylic acid, methacrylic acid, β-carboxyethyl (meth)acrylate, 5-carboxypentyl (meth)acrylate, succinic acid mono (meth)acryloyloxyethyl ester, ω-carboxypolycaprolactone mono (meth)acrylate, crotonic acid, maleic acid, fumaric acid, itaconic acid, citraconic acid, and carboxybetaine type monomers, and acrylic acid and methacrylic acid are preferred. The monomers having a carboxy group may be used alone or in combination of two or more.

[0032] Examples of the monomer having a sulfo group include p-styrenesulfonic acid, m-styrenesulfonic acid, o-styrenesulfonic acid, acrylamido t-butylsulfonic acid, vinylsulfonic acid, 2-(methacryloyloxy)ethanesulfonic acid, 3-(methacryloyloxy)propanesulfonic acid, 4-[(3-methacrylamidopropyl)dimethylammonio]butane-1-sulfonic acid, etc. The monomer having a sulfo group may be used alone or in combination of two or more kinds.

[0033] Examples of the monomer having a phosphonic acid group include vinyl phosphonic acid, alkyl vinyl phosphonate, etc. The monomer having a phosphonic acid group may be used alone or in combination of two or more kinds.

[0034] Examples of the monomer having a phosphoric acid group include monoacrylate phosphoric acid, diacrylate phosphoric acid, monomethacrylate phosphoric acid, dimethacrylate phosphoric acid, 2-hydroxyethyl methacrylic acid phosphoric acid, etc. The monomer having a phosphoric acid group may be used alone or in combination of two or more kinds.

[0035] When the organic acid is a polymer, the total content of monomer components having a carboxy group (-COOH), a sulfo group (-SOH), a phosphonic acid group [-P(=O)(OH)2] or a phosphate group [-OPO(OH)2] in the polymer is preferably 50 mass% or more, more preferably 60 mass% or more, more preferably 70 mass% or more, more preferably 80 mass% or more, more preferably 90 mass% or more, more preferably 95 mass% or more, more preferably 99 mass% or more, and more preferably 100 mass%.

[0036] A polymer having a carboxy group (-COOH), a sulfo group (-SOH), a phosphonic acid group [-P(=O)(OH)2] or a phosphoric acid group [-OPO(OH)2] in the side chain of a linear polymer may contain a monomer component copolymerizable with a monomer having a carboxy group (-COOH), a sulfo group (-SOH), a phosphonic acid group [-P(=O)(OH)2] or a phosphoric acid group [-OPO(OH)2].

[0037] Examples of the copolymerizable monomer include alkyl acrylates, alkyl methacrylates, vinyl alkyl ethers, vinyl acetate, ethylene, propylene, butylene, butadiene, diisobutylene, vinyl chloride, vinylidene chloride, 2-vinylnaphthalene, styrene, acrylonitrile, sodium acrylate, acrylamide, methacrylamide, diacetone acrylamide, vinyl toluene, vinyl pyridine, methyl methacrylate, sodium methacrylate, and hydroxyethyl methacrylate.

[0038] A polymer having a carboxy group (-COOH), a sulfo group (-SO3H), a phosphonic acid group [-P(=O)(OH)2] or a phosphoric acid group [-OPO(OH)2] in the side chain of a linear polymer can be produced by a general-purpose radical polymerization method.

[0039] The solubility of the organic acid in water at 25°C (solubility in water at 25°C) is preferably 20 g / L or less, more preferably 18 g / L or less. When the solubility of the organic acid in water at 25°C is 20 g / L or less, the interaction between the organic acid and viruses is improved, and an excellent virus infection inhibiting effect can be imparted to the virus infection inhibiting molded article. The solubility of the organic acid in water at 25°C refers to the mass of the organic acid that dissolves in 1 L of water.

[0040] The solubility of the organic acid in water at 25° C. is preferably 0.001 g / L or more, more preferably 0.01 g / L or more, and even more preferably 0.015 g / L or more. When the organic acid has a solubility in water at 25° C. of 0.001 g / L or more, the organic acid can improve the interaction between the organic acid and the virus when it comes into contact with an aqueous protein solution containing viruses, such as saliva or sputum, and can impart an excellent virus infection inhibiting effect to the virus infection-inhibiting molded article.

[0041] The solubility of organic acids in water at 25°C is the value measured at 25°C in accordance with OECD Chemicals Testing Guideline No. 105 (Water Solubility).

[0042] The virus infection inhibitor preferably contains an alkylbenzenesulfonate as an active ingredient. Examples of the alkylbenzenesulfonate include sodium dodecylbenzenesulfonate, potassium dodecylbenzenesulfonate, ammonium dodecylbenzenesulfonate, and triethanolammonium dodecylbenzenesulfonate.

[0043] The content of alkylbenzenesulfonate in the viral infection inhibitor is preferably 50% by mass or more, more preferably 60% by mass or more, more preferably 70% by mass or more, more preferably 80% by mass or more, more preferably 90% by mass or more, more preferably 95% by mass or more, more preferably 99% by mass or more, and more preferably 100% by mass.

[0044] The number of carbon atoms in the alkyl group of the alkylbenzene sulfonate is preferably 8 or more, more preferably 10 or more. The number of carbon atoms in the alkyl group of the alkylbenzene sulfonate is preferably 25 or less, more preferably 20 or less, and more preferably 18 or less. When the alkyl group has 8 or more carbon atoms, the dispersibility of the alkylbenzene sulfonate in the resin is increased, and the interaction between the alkylbenzene sulfonate and viruses is improved, thereby improving the viral infection-inhibiting effect of the viral infection-inhibiting molded article. When the alkyl group has 25 or less carbon atoms, the interaction between the alkylbenzene sulfonate and viruses is improved, and the viral infection-inhibiting effect of the viral infection-inhibiting molded article is improved.

[0045] The virus infection inhibitor preferably contains an amine compound as an active ingredient, such as a compound having at least one amino functional group selected from the group consisting of a primary amino group, a secondary amino group, and a tertiary amino group, or a salt thereof in the molecule.

[0046] The content of the amine compound in the virus infection inhibitor is preferably 50% by mass or more, more preferably 60% by mass or more, more preferably 70% by mass or more, more preferably 80% by mass or more, more preferably 90% by mass or more, more preferably 95% by mass or more, more preferably 99% by mass or more, and more preferably 100% by mass.

[0047] The amino functional group preferably contains a secondary amino group since the viral infection-inhibiting effect of the viral infection-inhibiting molded article is improved, and the amino functional group preferably contains a secondary amino group since it has a viral infection-inhibiting effect against both enveloped and non-enveloped viruses.

[0048] The amino functional group preferably forms a cyclic skeleton, and more preferably forms an alicyclic cyclic skeleton, since this not only improves the viral infection inhibitory effect of the viral infection inhibitor, but also can largely prevent whitening of the substrate surface even when the viral infection inhibitor is contained in a substrate and used.

[0049] The primary amino group refers to a monovalent substituent represented by -NH2. The secondary amino group refers to a divalent substituent (-NH-) resulting from removing (pulling out) one hydrogen atom from -NH2. The tertiary amino group refers to a trivalent substituent [≡N, formula (a)] resulting from removing (pulling out) two hydrogen atoms from -NH2. However, the amino functional group does not include a case where a keto group (>CO) is directly bonded to the nitrogen atom constituting the amino functional group.

[0050] [ka]

[0051] The salt of the amino functional group is not particularly limited, but an acid addition salt is preferred. Examples of the acid of the acid addition salt include hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, phosphorous acid, hydrobromic acid, maleic acid, malic acid, ascorbic acid, tartaric acid, lauric acid, stearic acid, palmitic acid, oleic acid, myristic acid, lauryl sulfuric acid, linoleic acid, and fumaric acid, and the hydrochloride is preferred.

[0052] The amine compound is preferably a polymeric compound having an amino functional group or a salt thereof, such as a polymer having an amino functional group or a salt thereof in the side chain of a linear polymer.

[0053] In the polymer containing an amino functional group or a salt thereof in the side chain of a linear polymer, the linear polymer is not particularly limited, and is preferably, for example, a vinyl polymer or a polyester, and more preferably a vinyl polymer.

[0054] Examples of polymers containing an amino functional group or a salt thereof in the side chain of a linear polymer include polymers containing, as monomer units, an amino functional group-containing monomer that contains an amino functional group or a salt thereof.

[0055] The amino functional group-containing monomer containing an amino functional group or a salt thereof is not particularly limited, and examples thereof include 2-vinylpyridine, 4-vinylpyridine, vinylimidazole, dimethylaminoethyl (meth)acrylate, diethylaminoethyl (meth)acrylate, t-butylaminoethyl (meth)acrylate, N-(aminoalkyl)acrylamide, N-(aminoalkyl)methacrylamide, a monomer obtained by reacting glycidyl (meth)acrylate with ammonia or dimethylamine, allylamine, diallylamine, methyldiallylamine, 1,2,2,6,6-pentamethyl-4-piperidyl methacrylate, 2,2,6,6-tetramethyl-4-piperidyl methacrylate, or salts of these amino functional groups. The amino functional group-containing monomer containing an amino functional group or a salt thereof may be used alone or in combination of two or more.

[0056] The polymer containing the amino-functional group-containing monomer as a monomer unit may be a homopolymer of the amino-functional group-containing monomer or a copolymer of the amino-functional group-containing monomer and a monomer copolymerizable therewith.

[0057] The monomer copolymerizable with the amino functional group-containing monomer is not particularly limited, and examples thereof include alkyl acrylate, alkyl methacrylate, vinyl alkyl ether, vinyl acetate, ethylene, propylene, butylene, butadiene, diisobutylene, vinyl chloride, vinylidene chloride, 2-vinylnaphthalene, styrene, acrylonitrile, acrylamide, methacrylamide, diacetone acrylamide, vinyl toluene, etc. The monomer copolymerizable with the amino functional group-containing monomer may be used alone or in combination of two or more kinds.

[0058] The content of the active ingredient in the viral infection inhibitor is preferably 50% by mass or more, more preferably 60% by mass or more, more preferably 70% by mass or more, more preferably 80% by mass or more, more preferably 90% by mass or more, more preferably 95% by mass or more, more preferably 99% by mass or more, and more preferably 100% by mass.

[0059] The virus infection inhibitor may be supported by a filler or may not be supported by a filler. The virus infection inhibitor may be configured in a particulate form by supporting the active ingredient (and any added ingredient) on the surface of a filler. The virus infection inhibitor may be configured not to be supported by a filler, but to have the active ingredient (and any added ingredient) processed into a particulate form by pulverization, granulation, or the like.

[0060] The filler is not particularly limited as long as it does not inhibit the virus infection inhibitory effect of the virus infection inhibitor. Examples of the filler include resin particles and inorganic particles. The filler may be used alone or in combination of two or more kinds.

[0061] Examples of synthetic resins constituting the resin particles include styrene-based resins, acrylic-based resins, urethane-based resins, vinyl chloride-based resins, ABS resins; and synthetic rubbers such as styrene-butadiene rubber (SBR) and nitrile-butadiene rubber (NBR).

[0062] The inorganic material constituting the inorganic particles is not particularly limited, and examples thereof include zeolite, hydrotalcite, calcium carbonate, calcium citrate, magnesium carbonate, and magnesium hydroxide.

[0063] The content of the viral infection inhibitor in the viral infection-blocking molded product is preferably 1 part by mass or more, more preferably 2 parts by mass or more, per 100 parts by mass of synthetic resin. The upper limit of the content of the viral infection inhibitor in the viral infection-blocking molded product is not particularly limited, but is preferably 80 parts by mass or less, more preferably 75 parts by mass or less, and more preferably 70 parts by mass or less, per 100 parts by mass of synthetic resin. When the content of the viral infection inhibitor is 1 part by mass or more, the viral infection-blocking molded product can be imparted with an excellent viral infection-blocking effect. When the content of the viral infection inhibitor is 80 parts by mass or less, the performance such as strength of the viral infection-blocking molded product can be easily ensured.

[0064] In the virus infection-blocking molded product, the content of the active ingredient is preferably 1 part by mass or more, more preferably 2 parts by mass or more, per 100 parts by mass of the synthetic resin. In the virus infection-blocking molded product, the upper limit of the content of the active ingredient is not particularly limited, but is preferably 80 parts by mass or less, more preferably 75 parts by mass or less, and more preferably 70 parts by mass or less, per 100 parts by mass of the synthetic resin. When the content of the active ingredient is 1 part by mass or more, the virus infection-blocking molded product can be imparted with an excellent virus infection-blocking effect. When the content of the active ingredient is 80 parts by mass or less, the performance such as the strength of the virus infection-blocking molded product can be easily ensured.

[0065] The inventors noticed that even when the same amount of viral infection inhibitor is contained in the synthetic resin that constitutes the viral infection-blocking molded body, there are differences in the viral infection-blocking effect due to the action of the viral infection inhibitor. After extensive research, the inventors discovered that the difference in the degree of aggregation of the viral infection inhibitor dispersed in the synthetic resin affects the viral infection-blocking effect of the viral infection-blocking molded body.

[0066] In detail, it has been found that the particulate virus infection inhibitor in the virus infection-blocking molding varies in its ease of presence on the surface of the virus infection-blocking molding depending on the degree of aggregation between the particles, and that the greater the degree of aggregation of the particulate virus infection inhibitor, the more likely it is to be present on the surface of the virus infection-blocking molding, improving the virus infection-blocking effect of the virus infection-blocking molding, while the greater the degree of aggregation of the particulate virus infection inhibitor, the smaller the surface area of ​​the virus infection inhibitor and the smaller the interaction between the virus and the virus.The present invention improves the virus infection-blocking effect of the virus infection-blocking molding by adjusting the degree of aggregation of the virus infection inhibitor in the synthetic resin to control the dispersion state.

[0067] For the virus infection inhibitor, the standard deviation σ of the volume fraction of the virus infection inhibitor in the width direction measured by X-ray CT (hereinafter sometimes simply referred to as "volume fraction") is 0.1 or more, preferably 0.11 or more, and more preferably 0.12 or more. For the virus infection inhibitor, the standard deviation σ of the volume fraction of the virus infection inhibitor in the width direction measured by X-ray CT is 5 or less, preferably 4 or less, and more preferably 3 or less. By adjusting the standard deviation σ of the volume fraction of the virus infection inhibitor within the above range, the virus infection inhibitor is moderately aggregated to prevent a decrease in surface area due to excessive aggregation of the virus infection inhibitor, while exposing more of the virus infection inhibitor to the surface of the virus infection inhibitor molding, thereby improving the virus infection inhibitory effect of the virus infection inhibitor molding.

[0068] For the viral infection-blocking molded article, the sphere-equivalent diameter measured by X-ray CT (hereinafter sometimes simply referred to as "sphere-equivalent diameter") is preferably 5 μm or more, more preferably 5.5 μm or more, and more preferably 6 μm or more. For the viral infection-blocking agent, the sphere-equivalent diameter measured by X-ray CT is preferably 30 μm or less, more preferably 25 μm or less, and more preferably 20 μm or less. When the sphere-equivalent diameter of the viral infection-blocking agent is within the above range, it is possible to prevent a decrease in surface area due to excessive aggregation of the viral infection-blocking agent, while allowing the viral infection-blocking agent to be moderately aggregated and exposed more on the surface of the viral infection-blocking molded article, thereby improving the viral infection-blocking effect of the viral infection-blocking molded article.

[0069] For the virus infection inhibitor, the standard deviation σ of the volume fraction of the virus infection inhibitor in the width direction measured by X-ray CT and the sphere equivalent diameter measured by X-ray CT are values ​​measured as follows.

[0070] For example, the measurement can be performed using the following measurement device and under the following measurement conditions. (X-ray CT using equipment) 3D X-ray microscope ("High-resolution 3D X-ray microscope nano3DX" manufactured by Rigaku Corporation) (X-ray CT measurement conditions) X-ray target: Cu Lens: L01080 (1.08μm / pixel) Binning: 2 Exposure time: 6 seconds Number of shots: 1000 Sample set: Set so that the thickness direction is the Z axis (Image analysis) (i) Image stitching: In the case of samples that span multiple fields of view, the images are stitched. (ii) Horizontal correction: Using the Transform Editor, adjust the surface of the virus infection-blocking molded object so that it is horizontal in the image, and then apply Resample Transformed Image. In Resample Transformed Image, change the Mode to extended, and leave other conditions at their default values. (iii) Extraction of virus-infection-blocking molded body regions: Interactive Thresholding is applied to the image of (ii) and the threshold is adjusted so that only the virus-infection-blocking molded body regions are extracted. (iv) Extraction of viral infection inhibitors: Interactive Thresholding is applied to the image in (iii) and the threshold is adjusted so that only the viral infection inhibitor regions are extracted. (v) Region division process: Separate Objects is applied to the image of (iv) to divide adjacent virus infection inhibitor regions into each region. The conditions for Separate Objects are as follows. Note that the conditions for Separate Objects can be changed as appropriate depending on the shooting conditions and the type of molded body. Marker Extent:3 All other conditions will remain at their default values. (vi) Image edge processing: Border Kill is applied to the image in (iv) to remove the virus infection inhibitor extraction area that is adjacent to the image edge. Note that the Border Kill conditions are set to the initial values. (vii) Calculation of the volume ratio in the width direction: Material Statistics is applied to the images in (iii) and (iv) to measure the volume of each region in each cross section in the width direction. The conditions for Material Statistics are as follows: Select:Volume per slice From the measured volume, the volume fraction of the viral infection inhibitor at each cross section in the width direction is calculated using the following formula. Volume ratio of virus infection inhibitor (%) = Volume of virus infection inhibitor / Volume of virus infection inhibitor molded body × 100 Furthermore, the standard deviation is calculated from the volume ratio of the virus infection inhibitor in each cross section in the width direction. (viii) Calculation of sphere-equivalent diameter: Label analysis is applied to the image in (v) to analyze the volume (voxel) of each virus infection inhibitor extraction area. The actual volume is calculated from the obtained volumes using the following formula. Actual volume (μm 3) = volume (voxel) × (resolution) 3 (μm / pixel) Furthermore, the sphere-equivalent diameter is calculated from the actual volume using the following formula. Sphere equivalent diameter (μm) = 2 × [(3 × actual volume) / (4π)]^(1 / 3)

[0071] The standard deviation σ of the volume fraction of the virus infection inhibitor can be controlled, for example, in the following manner. For example, (1) the standard deviation σ of the volume fraction of the virus infection inhibitor can be reduced by increasing the degree of kneading of the synthetic resin and the virus infection inhibitor. (2) The standard deviation σ of the volume fraction of the virus infection inhibitor can be reduced by using a larger amount of a dispersant, which will be described later, when mixing the synthetic resin and the virus infection inhibitor.

[0072] The sphere-equivalent diameter of the viral infection inhibitor can be controlled, for example, in the following manner. For example, (1) the sphere-equivalent diameter of the viral infection inhibitor can be reduced by increasing the degree of kneading of the synthetic resin and the viral infection inhibitor. (2) The sphere-equivalent diameter of the viral infection inhibitor can be reduced by using a larger amount of dispersant when mixing the synthetic resin and the viral infection inhibitor. (3) The sphere-equivalent diameter of the viral infection inhibitor can be reduced by reducing the particle diameter of the particulate viral infection inhibitor before mixing with the synthetic resin.

[0073] [Dispersant] The virus infection-blocking molded article preferably contains a dispersant. By containing a dispersant in the virus infection-blocking molded article, the particulate virus infection-blocking agent is appropriately aggregated to form aggregated particles of an optimal size, which makes it easier for the agent to be present on the surface of the virus infection-blocking molded article, and the surface area of ​​the virus infection-blocking agent is increased, thereby making it possible to improve the virus infection-blocking effect of the virus infection-blocking molded article.

[0074] The dispersant is not particularly limited, and examples thereof include anionic surfactants (excluding alkylbenzenesulfonates) (hereinafter, sometimes simply referred to as "anionic surfactants"), cationic surfactants, nonionic surfactants, amphoteric surfactants, polyalkylene glycols (e.g., polyethylene glycol, polypropylene glycol, etc.), and polymers having a salt of a sulfo group in the side chain of a linear polymer, and anionic surfactants (excluding alkylbenzenesulfonates), nonionic surfactants, polyalkylene glycols, and polymers having a salt of a sulfo group in the side chain of a linear polymer are preferred.

[0075] The dispersant preferably contains an anionic surfactant (excluding alkylbenzene sulfonate) and a nonionic surfactant, and more preferably contains a compound containing a salt of a sulfo group in the molecule (excluding alkylbenzene sulfonate) and a nonionic surfactant. The dispersant preferably contains an anionic surfactant (excluding alkylbenzene sulfonate) and a compound containing a polyoxyalkylene structure in the molecule. The dispersant more preferably contains a compound containing a salt of a sulfo group in the molecule (excluding alkylbenzene sulfonate) and a compound containing a polyoxyalkylene structure in the molecule. By using the above two types of dispersants in combination, the virus infection inhibitor can be made into aggregate particles of a more appropriate size, and the virus infection inhibitory effect of the virus infection inhibitory molded article can be improved.

[0076] The anionic surfactant is not particularly limited, and examples thereof include alkyl phosphates such as sodium dodecyl phosphate, potassium dodecyl phosphate, sodium stearyl phosphate, and potassium stearyl phosphate; polyoxyethylene alkyl ether phosphate salts such as polyoxyethylene (3) lauryl ether sodium phosphate and polyoxyethylene (3) lauryl ether potassium phosphate; polyoxyethylene alkyl phenyl ether phosphate salts such as polyoxyethylene (3) lauryl phenyl ether sodium phosphate and polyoxyethylene (3) lauryl phenyl ether potassium phosphate; polystyrene sulfonate, α-olefin sulfonate, alkyl diphenyl ether sulfonate, and polyoxyalkylene alkyl ether sulfate salts; and compounds containing a salt of a sulfo group (-SO3H) in the molecule, such as polystyrene sulfonate, are preferred.

[0077] It is preferable that the dispersant is a compound containing a salt of a sulfo group (-SO3H) in the molecule, because the interaction between the viral infection inhibitor and the dispersant improves the interaction of the viral infection inhibitor with the virus, thereby improving the viral infection inhibiting effect of the viral infection inhibiting molded article.

[0078] The nonionic surfactant is not particularly limited, and examples thereof include polyoxyalkylene alkyl ethers (e.g., polyoxyethylene lauryl ether, polyoxyethylene cetyl ether, polyoxyethylene oleyl cetyl ether, polyoxyethylene stearyl ether, polyoxyethylene oleyl ether, polyoxyethylene polyoxypropylene lauryl ether, and other polyoxyethylene alkyl ethers, polyoxypropylene cetyl ether, polyoxypropylene isocetyl ether, polyoxypropylene stearyl ether, polyoxypropylene oleyl ether, and other polyoxypropylene alkyl ethers), polyoxyethylene alkyl phenyl ethers, polyoxyalkylene fatty acid esters (e.g., polyoxyethylene fatty acid esters such as polyethylene glycol monostearate and polyethylene glycol distearate, polyoxypropylene fatty acid esters such as polypropylene glycol monostearate and polypropylene glycol distearate), and polyoxyethylene distyrenated phenyl ether. , sorbitan fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene sorbitol fatty acid esters, glycerin fatty acid esters, polyoxyethylene glycerin fatty acid esters, polyglycerin fatty acid esters, sucrose fatty acid esters, polyoxyethylene alkylamines, polyoxyethylene fatty acid amides, fatty acid alkanolamides (e.g., coconut fatty acid alkanolamides such as lauric acid diethanolamide, coconut fatty acid dimethanolamide, coconut fatty acid diethanolamide, and coconut fatty acid dipropanolamide), fatty acid alkylolamides, alkyl alkanolamides, acetylene glycol, oxyethylene adducts of acetylene glycol, and polyethylene glycol polypropylene glycol block copolymers. Polyoxyalkylene alkyl ethers, polyoxyalkylene fatty acid esters, and fatty acid alkanolamides are preferred, and polyoxyethylene alkyl ethers, polyoxyethylene fatty acid esters, and fatty acid ethanolamides (saturated fatty acid ethanolamides are preferred) are more preferred.

[0079] The amphoteric surfactant is not particularly limited, and examples thereof include alkylaminoacetic acid betaine, alkylamidopropyl betaine, sulfobetaine, alkylamino (mono- or di-)propionate, imidazolinium betaine, alkylamine oxide, alkylaminoethyl glycine, alkyldi(aminoethyl)glycine, glycine n-(3-aminopropyl) C10-16 derivative, alkylpolyaminoethylglycine, alkyl β-alanine, alkyldiethanolamine, polyoxyalkylene alkylamine, and oxyethylene addition type surfactant of diamine.

[0080] In the polymer having a salt of a sulfo group in the side chain of a linear polymer, the linear polymer is not particularly limited, and for example, vinyl polymers, polyesters, and polyurethanes are preferred, with vinyl polymers being preferred.

[0081] The polymer having a salt of a sulfo group in the side chain of a linear polymer is not particularly limited, and examples thereof include a polymer containing a styrene sulfonate component, a styrene sulfonate homopolymer, a styrene-styrene sulfonate copolymer, a sulfonate of a compound obtained by sulfonating the benzene ring of polystyrene, and a sulfonate of a compound obtained by sulfonating the benzene ring of a polymer containing a styrene component.

[0082] Also, the polymer having a salt of a sulfo group in the side chain of the linear polymer is preferably a homopolymer or copolymer of a monomer having a salt of a sulfo group. Examples of the monomer having a salt of a sulfo group include sodium p-styrenesulfonate, sodium m-styrenesulfonate, sodium o-styrenesulfonate, calcium p-styrenesulfonate, calcium m-styrenesulfonate, calcium o-styrenesulfonate, ammonium p-styrenesulfonate, ammonium m-styrenesulfonate, ammonium o-styrenesulfonate, sodium naphthalenesulfonate, and calcium naphthalenesulfonate. Sodium styrenesulfonate is preferred, and sodium p-styrenesulfonate is more preferred because it has less steric hindrance in reactivity with viruses.

[0083] The monomer having a salt of a sulfo group may be copolymerized with other monomers. Examples of copolymerizable monomers include alkyl acrylate, alkyl methacrylate, vinyl alkyl ether, vinyl acetate, ethylene, propylene, butylene, butadiene, diisobutylene, vinyl chloride, vinylidene chloride, 2-vinylnaphthalene, styrene, acrylonitrile, acrylic acid, sodium acrylate, methacrylic acid, maleic acid, fumaric acid, maleic anhydride, acrylamide, methacrylamide, diacetone acrylamide, vinyl toluene, xylene sulfonic acid, vinyl pyridine, vinyl sulfonic acid, vinyl alcohol, methyl methacrylate, sodium methacrylate, and hydroxyethyl methacrylate, with styrene being preferred.

[0084] A polymer having a salt of a sulfo group in the side chain of a linear polymer can be produced by a general method, and examples of such methods include a method of radically polymerizing a monomer having a salt of a sulfo group, a method of radically polymerizing a monomer having a salt of a sulfo group and a monomer copolymerizable with this monomer, and a method of neutralizing the sulfo group of a polymer containing a monomer component having a sulfo group with an alkali (e.g., sodium hydroxide, calcium hydroxide, potassium hydroxide, ammonium hydroxide, etc.).

[0085] The weight average molecular weight of the linear polymer having a salt of a sulfo group in its side chain is preferably not less than 3000, preferably not less than 5000, more preferably not less than 10000, and more preferably not less than 100000. When the weight average molecular weight of the linear polymer having a salt of a sulfo group in its side chain is not less than 3000, the compatibility of the linear polymer having a salt of a sulfo group in its side chain with the synthetic resin is improved, and the dispersibility of the viral infection inhibitor in the synthetic resin can be improved.

[0086] The weight average molecular weight of the linear polymer having a sulfo salt in its side chain is preferably not more than 1,000,000, more preferably not more than 900,000, more preferably not more than 800,000, and more preferably not more than 500,000. When the weight average molecular weight of the linear polymer having a sulfo salt in its side chain is not more than 1,000,000, the linear polymer having a sulfo salt in its side chain can be easily brought into close proximity with the viral infection inhibitor, and the dispersibility of the viral infection inhibitor in the synthetic resin can be improved.

[0087] In the present invention, the weight average molecular weight of the linear polymer having a salt of a sulfo group in its side chain is a value calculated in terms of polystyrene measured by GPC (gel permeation chromatography).

[0088] For example, the measurement can be performed using the following measurement device and under the following measurement conditions. Gel permeation chromatograph: Waters product name "2690 Separations Model" Column: Showa Denko Co., Ltd. Product name "GPC KF-806L" Detector: Differential refractometer Sample flow rate: 1mL / min Column temperature: 40℃ Eluent: THF

[0089] The dispersant preferably contains a polyoxyalkylene structure in the molecule, more preferably a polyoxyethylene structure. The dispersant containing a polyoxyalkylene structure in the molecule acts to cause the virus infection inhibitor, particularly the organic acid, to segregate (bleed out) on the surface of the virus infection-inhibiting molded article, so that the virus infection-inhibiting molded article exhibits an excellent virus infection-inhibiting effect.

[0090] The polyoxyalkylene structure means a repeating unit represented by the following general formula. -(R 1 -O)n- (In the formula, R 1represents an alkylene group having 1 to 3 carbon atoms, and n is the number of repeating units and is a natural number of 2 or more.

[0091] An alkylene group is a divalent atomic group resulting from the removal of two hydrogen atoms bonded to two different carbon atoms in an aliphatic saturated hydrocarbon, and includes both linear and branched atomic groups. Note that branched includes the case where one carbon (methyl group) is bonded as a side chain.

[0092] Examples of the alkylene group include an ethylene group, a propylene group [-CH(CH3)-CH2-], a trimethylene group [-CH2-CH2-CH2-], a butylene group, an amylene group [-(CH2)5-], and a hexylene group, with an ethylene group and a propylene group being preferred, and an ethylene group being more preferred.

[0093] The content of the dispersant in the virus infection-blocking molded product is preferably 0.1 parts by mass or more, more preferably 0.15 parts by mass or more, and more preferably 0.2 parts by mass or more, relative to 100 parts by mass of the synthetic resin. The content of the dispersant in the virus infection-blocking molded product is preferably 30 parts by mass or less, more preferably 20 parts by mass or less, and more preferably 10 parts by mass or less, relative to 100 parts by mass of the synthetic resin. When the content of the dispersant is 0.1 parts by mass or more, an excellent virus infection-blocking effect can be imparted to the virus infection-blocking molded product. When the content of the dispersant is 30 parts by mass or less, the virus infection-blocking agent is not covered by the dispersant, and the interaction with the virus is improved, resulting in an improved virus infection-blocking effect.

[0094] In the virus infection-blocking molded product, the ratio of the content of the virus infection inhibitor to the content of the dispersant (mass of the virus infection inhibitor / mass of the dispersant) is preferably 0.5 or more, more preferably 0.6 or more, and more preferably 0.7 or more. In the virus infection-blocking molded product, the ratio of the content of the virus infection inhibitor to the content of the dispersant (mass of the virus infection inhibitor / mass of the dispersant) is preferably 20 or less, more preferably 18 or less, and more preferably 16 or less. When the ratio of the content of the virus infection inhibitor to the content of the dispersant (mass of the virus infection inhibitor / mass of the dispersant) is 0.5 or more, the virus infection-blocking effect can be easily obtained while ensuring the performance such as the strength of the virus infection-blocking molded product. When the ratio of the content of the virus infection inhibitor to the content of the dispersant (mass of the virus infection inhibitor / mass of the dispersant) is 20 or less, the dispersibility of the virus infection inhibitor in the synthetic resin is increased, the interaction between the virus infection inhibitor and the virus is improved, and the virus infection-blocking effect of the virus infection-blocking molded product is improved.

[0095] In the virus infection-blocking molded article, the ratio of the content of the alkylbenzene sulfonate to the content of the dispersant (mass of alkylbenzene sulfonate / mass of dispersant) is preferably 0.5 or more, more preferably 0.6 or more, and more preferably 0.7 or more. In the virus infection-blocking molded article, the ratio of the content of the alkylbenzene sulfonate to the content of the dispersant (mass of alkylbenzene sulfonate / mass of dispersant) is preferably 20 or less, more preferably 18 or less, and more preferably 16 or less. When the ratio of the content of the alkylbenzene sulfonate to the content of the dispersant (mass of alkylbenzene sulfonate / mass of dispersant) is 0.5 or more, the virus infection-blocking effect can be easily obtained while ensuring the performance such as the strength of the virus infection-blocking molded article. When the ratio of the content of the alkylbenzene sulfonate to the content of the dispersant (mass of alkylbenzene sulfonate / mass of dispersant) is 20 or less, the dispersibility of the virus infection-blocking agent in the synthetic resin is increased, the interaction between the virus infection-blocking agent and the virus is improved, and the virus infection-blocking effect of the virus infection-blocking molded article is improved.

[0096] In the virus infection-blocking molded product, the ratio of the amine compound content to the dispersant content (mass of amine compound / mass of dispersant) is preferably 0.5 or more, more preferably 0.6 or more, and more preferably 0.7 or more. In the virus infection-blocking molded product, the ratio of the amine compound content to the dispersant content (mass of amine compound / mass of dispersant) is preferably 20 or less, more preferably 18 or less, and more preferably 16 or less. When the ratio of the amine compound content to the dispersant content (mass of amine compound / mass of dispersant) is 0.5 or more, the virus infection-blocking effect can be easily obtained while ensuring the performance such as the strength of the virus infection-blocking molded product. When the ratio of the amine compound content to the dispersant content (mass of amine compound / mass of dispersant) is 20 or less, the dispersibility of the virus infection-blocking agent in the synthetic resin is increased, the interaction between the virus infection-blocking agent and the virus is improved, and the virus infection-blocking effect of the virus infection-blocking molded product is improved.

[0097] [Virus infection prevention molding] The virus infection-inhibiting molded article can be produced by adding a dispersant to a particulate virus infection inhibitor and a synthetic resin, if necessary, melting them, and mixing them in a general manner. For example, a resin composition obtained by adding a dispersant to a particulate virus infection inhibitor and a synthetic resin if necessary is molded by a general synthetic resin molding method to produce a virus infection-inhibiting molded article having a desired shape. Examples of general synthetic resin molding methods include extrusion molding, injection molding, and blow molding.

[0098] In the virus infection-blocking molded product, the particulate virus infection-blocking agent is dispersed in the synthetic resin while agglomerating to a suitable size to form aggregated particles, and the virus infection-blocking agent is configured to segregate on the surface of the virus infection-blocking molded product while increasing the surface area of ​​the virus infection-blocking agent. Therefore, the virus infection-blocking agent in the virus infection-blocking molded product effectively interacts with the virus, and the virus infection-blocking molded product exhibits excellent virus infection-blocking effect.

[0099] A synthetic resin masterbatch may be produced by mixing a synthetic resin containing a virus infection inhibitor and, if necessary, a dispersant, and this synthetic resin masterbatch may be used to produce a virus infection inhibitor molded article having a desired shape using the above-mentioned general-purpose synthetic resin molding method. The synthetic resin used in the synthetic resin masterbatch may be any of the synthetic resins exemplified above. Only one type of synthetic resin may be used, or two or more types may be used in combination.

[0100] The synthetic resin molding masterbatch is preferably in the form of resin pellets because of its excellent moldability. By melting and molding the resin pellets, a synthetic resin molded product having excellent virus infection prevention effects can be obtained.

[0101] The shape of the resin pellet is not particularly limited, and examples thereof include a spherical shape, a cylindrical shape, and a prismatic shape. From the viewpoint of the stability of the pellet shape, a cylindrical shape is preferred. The maximum length dimension of the resin pellet is preferably 1 mm or more, more preferably 3 mm or more. The maximum length dimension of the resin pellet is preferably 10 mm or less, more preferably 7 mm or less.

[0102] The synthetic resin molding master batch can be used by mixing with other resin materials. The other resin materials may be resin pellets. The synthetic resin molding master batch and the other resin materials are mixed to obtain a mixed resin material, and then the mixed resin material is molded to obtain a virus infection-preventing molded article having excellent virus infection-preventing effect.

[0103] The content of the virus infection inhibitor in the synthetic resin molding masterbatch is preferably 10 parts by mass or more, more preferably 15 parts by mass or more, and more preferably 20 parts by mass or more, per 100 parts by mass of the synthetic resin. The content of the virus infection inhibitor in the synthetic resin molding masterbatch is preferably 80 parts by mass or less, more preferably 70 parts by mass or less, and more preferably 60 parts by mass or less, per 100 parts by mass of the synthetic resin.

[0104] The content of the dispersant in the synthetic resin molding masterbatch is preferably 3 parts by mass or more, more preferably 5 parts by mass or more, more preferably 8 parts by mass or more, and more preferably 10 parts by mass or more, relative to 100 parts by mass of the synthetic resin. The content of the dispersant in the synthetic resin molding masterbatch is preferably 40 parts by mass or less, more preferably 30 parts by mass or less, and more preferably 20 parts by mass or less, relative to 100 parts by mass of the synthetic resin. EXAMPLES

[0105] The present invention will be described in more detail below using examples, but the present invention is not limited thereto.

[0106] The compounds shown below were used as synthetic resins. [Synthetic resin] ·polypropylene

[0107] The compounds shown below were used as agents for inhibiting viral infection. [Virus infection inhibitor] (organic acid) Terephthalic acid (average particle size: 50 μm) · Alginic acid (average particle size: 50 μm) Isophthalic acid (average particle size: 50 μm) (Alkylbenzenesulfonate) Sodium dodecylbenzenesulfonate (average particle size: 50 μm)

[0108] The compounds shown below were used as dispersants. [Dispersant 1 (containing sulfo group salt)] (Anionic surfactants) Sodium lauryl sulfonate (average particle size: 50 μm) Sodium polystyrene sulfonate (average particle size: 50 μm, weight average molecular weight: 200,000)

[0109] [Dispersant 2 (non-sulfo group salt)] (Nonionic surfactant) Polyethylene glycol distearate Polyethylene glycol monostearate Polyoxyethylene lauryl ether Lauric acid diethanolamide (Other dispersants) Polyethylene glycol

[0110] (Examples 1 to 19, Comparative Examples 1 to 7) The types of virus infection inhibitors shown in Table 1 were prepared. The types of anionic surfactants shown in Table 1 were prepared as dispersant 1. The types of nonionic surfactants and polyethylene glycol shown in Table 1 were prepared as dispersant 2.

[0111] A masterbatch for synthetic resin molding was prepared by melt-kneading and mixing polypropylene, the type of virus infection inhibitor shown in Table 1, and the types of dispersants 1 and 2 shown in Table 1 in the mass ratio (parts by mass) of the masterbatch shown in Table 1. The amount of each component is shown in the "Mass ratio of masterbatch" column of Table 1 as "mass of polypropylene / mass of virus infection inhibitor / mass of dispersant 1 / mass of dispersant 2." The "Virus infection inhibitor / dispersant" column shows the mass ratio (mass of virus infection inhibitor / total mass of dispersant) of the content of the virus infection inhibitor to the content of the dispersant (total content of dispersant 1 and dispersant 2).

[0112] The synthetic resin molding master batch obtained and a separately prepared polypropylene (manufactured by Japan Polypropylene Corporation, product name "Novatec PP BC6C") were supplied to a kneading device (manufactured by Toyo Seiki Seisakusho, product name "Labo Plastomill 3S150") so that the polypropylene, the type of virus infection inhibitor shown in Table 1, and the dispersants 1 and 2 shown in Table 1 were in the mass ratio (parts by mass) of the resin composition (molded body) shown in Table 1, and melt-kneaded under the kneading conditions shown in Table 2 using a roller mixer R60 (manufactured by Toyo Seiki Seisakusho), to prepare a resin composition. In the column "mass ratio of resin composition (molded body)" in Table 1, the amount of each component is shown in the notation "mass of polypropylene / mass of virus infection inhibitor / mass of dispersant 1 / mass of dispersant 2". In the kneading conditions 1 to 3, the kneading temperature (°C), the rotation speed (rpm) during kneading, and the kneading time (min) are shown in Table 2.

[0113] The obtained resin composition was press-molded to obtain a sheet-like virus infection-inhibiting molded article having an average thickness of 1 mm. In the virus infection-inhibiting molded article, the particulate virus infection-inhibiting agent was contained in a dispersed state in polypropylene.

[0114] For the obtained virus infection-inhibiting molding, the standard deviation σ of the volume fraction of the particulate virus infection inhibitor in the width direction measured by X-ray CT was measured in the manner described above, and the results are shown in the ``Standard deviation σ'' column in Table 1.

[0115] The sphere-equivalent diameter of the particulate viral infection inhibitor obtained in the viral infection-inhibiting molded article was measured by X-ray CT in the manner described above, and the results are shown in the "sphere-equivalent diameter" column in Table 1.

[0116] The antiviral activity of the obtained virus infection-inhibiting molded article was measured in the manner described below, and the results are shown in Table 1.

[0117] [Virus infection prevention effect] The obtained virus infection-blocking molded article was subjected to an antiviral test using influenza virus (envelope virus) in the following manner.

[0118] (Antiviral test) Test pieces were prepared by cutting out a flat square piece of the virus infection-blocking molding with each side measuring 5.0 cm.

[0119] The surface of the obtained test piece was wiped with a flat square nonwoven fabric measuring 10 cm on a side (manufactured by Nippon Paper Crecia Co., Ltd., product name "Kimwipe S-200") by wiping it back and forth 10 times to prepare a test specimen.

[0120] The obtained test specimens were subjected to an antiviral test (test time: 24 hours) for influenza virus in accordance with ISO21702. The virus suspension was used 10 minutes after the reaction (start of the test) to measure the virus infectivity (common logarithm value) (PFU / cm) of the test specimens by the plaque method. 2 ) was calculated.

[0121] A blank standard was prepared in the same manner as above, except that no virus infection inhibitor was added, and the virus infectivity (common logarithm value) (PFU / cm) was calculated based on this blank standard in the same manner as above. 2 ) was calculated.

[0122] The initial antiviral activity value was calculated by subtracting the viral infectivity of the test sample from the viral infectivity of the blank reference sample.

[0123] [Table 1]

[0124] [Table 2]

Claims

1. A synthetic resin and a particulate virus infection inhibitor contained in a dispersed state in the synthetic resin, A virus infection-inhibiting molded article characterized in that the standard deviation σ of the volume fraction of the virus infection inhibitor in the width direction measured by X-ray CT is 0.1 to 5.

2. 2. The virus infection-inhibiting molded article according to claim 1, characterized in that the virus infection-inhibiting agent contains at least any one of organic acids, alkylbenzene sulfonates, and amine compounds as an active ingredient.

3. 3. The virus infection-inhibiting molded article according to claim 2, wherein the active ingredient of the virus infection inhibitor contains an organic acid.

4. 3. The virus infection-preventing molded article according to claim 1, further comprising a dispersant.

5. 5. The virus infection-preventing molded article according to claim 4, wherein the dispersant contains a compound containing a salt of a sulfo group in the molecule and / or a compound containing a polyoxyalkylene structure in the molecule.

6. 5. The virus infection-inhibiting molded article according to claim 4, characterized in that the ratio of the content of the virus infection inhibitor to the content of the dispersant (mass of virus infection inhibitor / mass of dispersant) is 0.5 to 20.

7. 3. The virus infection-inhibiting molded article according to claim 1, wherein the virus infection-inhibiting agent has an equivalent sphere diameter of 5 to 30 μm as measured by X-ray CT.

8. 2. The method for producing a virus infection-inhibiting molded article according to claim 1, further comprising a step of melt-kneading a particulate virus infection-inhibiting agent and a synthetic resin.

Images